A "bulldozer" driven by anoxic bacteria for pancreatic cancer chemo-immunotherapy

被引:12
|
作者
Zhang, Huijuan [1 ,2 ,3 ,5 ]
Wang, Yaping [1 ]
Zhu, Ling [1 ,2 ]
Qi, Zijun [1 ]
Cao, Kexuan [1 ]
Chang, Junbiao [3 ,4 ,5 ]
Hou, Lin [1 ,2 ,5 ]
机构
[1] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou, Peoples R China
[2] Key Lab Targeting Therapy & Diag Crit Dis, Zhengzhou, Henan Province, Peoples R China
[3] Collaborat Innovat Ctr New Drug Res & Safety Evalu, Zhengzhou, Henan Province, Peoples R China
[4] Zhengzhou Univ, Sch Chem & Mol Engn, Zhengzhou, Peoples R China
[5] Zhengzhou Univ, Sch Pharmaceut Sci, 100, Kexue Rd, Zhengzhou 450001, Peoples R China
基金
中国国家自然科学基金;
关键词
PDAC; Tumor matrix barrier; ICD; Autophagy inhibition; Immunotherapy; IMMUNOGENIC CELL-DEATH;
D O I
10.1016/j.jconrel.2023.07.014
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Immune evasion is a major obstacle for pancreatic ductal adenocarcinoma (PDAC) therapy. Inhibition of autophagy can improve antigen presentation and enlarge immunogenic cell death (ICD) effect to generate a strong anti-tumor immune response. However, abundant extracellular matrix dominated by hyaluronic acid (HA) hinders the deep penetration of autophagy inhibitors and ICD inducers. Herein, an intelligent autophagy inhibitor hydroxychloroquine (HCQ) and chemotherapeutic drug doxorubicin (DOX) co-loaded "bulldozer" (HD@HH/EcN) driven by anoxic bacteria was constructed for PDAC chemo-immunotherapy. Results demonstrated that probiotic Escherichia coli 1917 (EcN) could carry hyaluronidases (HAases)-hybrided albumin nanoparticles (HD@HH) to reach PDAC tumor tissue quickly and accurately. Thereafter, HAases can efficiently cleave the tumor matrix barrier and promote HD@HH/EcN to accumulate at tumor hypoxic core significantly. After that, high level of glutathione (GSH) in tumor microenvironment (TME) induces intermolecular disulfide bond in HD@HH nanoparticles breakage, to precisely release HCQ and DOX. DOX can induce ICD effect. Meanwhile, HCQ can amplify DOX induced ICD effect by inhibiting tumor autophagy, which further increase cell surface expression of major histocompatibility complex class I (MHC-I) and augment recruitment of CD8+ T cell to improve immunosuppressive TME. This study provides a new strategy for PDAC chemo-immunotherapy.
引用
收藏
页码:660 / 671
页数:12
相关论文
共 50 条
  • [31] Tumor Clearance Analysis on a Cancer Chemo-Immunotherapy Mathematical Model
    Paul A. Valle
    Luis N. Coria
    Yolocuauhtli Salazar
    Bulletin of Mathematical Biology, 2019, 81 : 4144 - 4173
  • [32] PROCALCITONIN FLUCTUATION AFTER CHEMO-IMMUNOTHERAPY IN PATIENTS WITH LUNG CANCER
    ARROYO-HERNANDEZ, M.
    CABRERA-MIRANDA, L.
    MONRAZ-PEREZ, S.
    JAIME, M. E.
    RAMOS-RAMIREZ, M.
    CONDE-FLORES, E.
    MARTINEZ-BRISENO, D.
    LOPEZ, D.
    CARDONA, A. F.
    ARRIETA, O.
    CHEST, 2022, 161 (06) : 307A - 307A
  • [33] Development of Facile and Versatile Platinum Drug Delivering Silicasome Nanocarriers for Efficient Pancreatic Cancer Chemo-Immunotherapy
    Liu, Xiangsheng
    Jiang, Jinhong
    Chang, Chong Hyun
    Liao, Yu-Pei
    Lodico, Jared J.
    Tang, Ivanna
    Zheng, Emily
    Qiu, Waveley
    Lin, Matthew
    Wang, Xiang
    Ji, Ying
    Mei, Kuo-Ching
    Nel, Andre E.
    Meng, Huan
    SMALL, 2021, 17 (14)
  • [34] Tumor Clearance Analysis on a Cancer Chemo-Immunotherapy Mathematical Model
    Valle, Paul A.
    Coria, Luis N.
    Salazar, Yolocuauhtli
    BULLETIN OF MATHEMATICAL BIOLOGY, 2019, 81 (10) : 4144 - 4173
  • [35] A CONTROLLED-STUDY OF MAINTENANCE CHEMO-IMMUNOTHERAPY VS IMMUNOTHERAPY ALONE IMMEDIATELY FOLLOWING PALLIATIVE GASTRECTOMY AND INDUCTION CHEMO-IMMUNOTHERAPY FOR ADVANCED GASTRIC-CANCER
    YASUE, M
    MURAKAMI, M
    NAKAZATO, H
    SUCHI, T
    OTA, K
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1981, 7 (01) : 5 - 10
  • [36] CHEMO-IMMUNOTHERAPY TO TREAT BONE-METASTATIC PROSTATE CANCER
    Kumar, Shreya
    Figueiredo, Marxa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A586 - A586
  • [37] CHEMO-IMMUNOTHERAPY FOR UNRESECTABLE BRONCHOGENIC CARCINOMA
    SARNA, GP
    LOWITZ, BB
    HASKELL, CM
    DOREY, FJ
    CLINE, MJ
    CANCER TREATMENT REPORTS, 1978, 62 (05): : 681 - 687
  • [38] CHEMO-IMMUNOTHERAPY IN HODGKINS-DISEASE
    ADVANI, SH
    GANGAL, SG
    DINSHAW, KA
    GOPAL, R
    NAIR, CN
    TALWALKAR, GV
    DESAI, PB
    CANCER TREATMENT REPORTS, 1982, 66 (04): : 1065 - 1065
  • [39] Chemo-immunotherapy in RCC: the end of a story
    Escudier, Bernard
    LANCET, 2010, 375 (9715): : 613 - 614
  • [40] Chemo-immunotherapy of advanced malignant melanoma
    Kirchner, HH
    Atzpodien, J
    Poliwoda, H
    MEDIZINISCHE KLINIK, 1996, 91 : 44 - 49